Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
07 09 2019
Historique:
received: 17 08 2019
revised: 27 08 2019
accepted: 05 09 2019
entrez: 11 9 2019
pubmed: 11 9 2019
medline: 28 7 2020
Statut: epublish

Résumé

Although lung adenocarcinomas (LADs) with ground-glass opacity (GGO; part-solid tumors) have been shown to differ from those without GGO (pure-solid tumors) in clinicopathological features and prognoses, whether programmed death ligand-1 (PD-L1) protein expression differs between these two tumor types is unclear. This study included 124 patients with clinical T1a-c LAD who received pulmonary resections during 2007-2009. The E1L3N antibody was used to stain for PD-L1 in primary LAD specimens. The specimens were considered PD-L1

Identifiants

pubmed: 31500267
pii: biom9090456
doi: 10.3390/biom9090456
pmc: PMC6769535
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Lung Cancer. 2017 Nov;18(6):e375-e383
pubmed: 28385373
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Thorac Oncol. 2017 Sep;12(9):1403-1412
pubmed: 28627462
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Lung Cancer. 2016 Aug;98:69-75
pubmed: 27393509
Lancet. 2016 Sep 3;388(10048):1012-24
pubmed: 27598681
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Thorac Oncol. 2019 Jun;14(6):968-978
pubmed: 30851441
J Thorac Oncol. 2019 Feb;14(2):265-275
pubmed: 30368010
J Thorac Oncol. 2016 Aug;11(8):1204-1223
pubmed: 27107787
Clin Lung Cancer. 2018 Jan;19(1):e47-e51
pubmed: 28743420
JAMA Oncol. 2017 Aug 1;3(8):1051-1058
pubmed: 28278348
J Thorac Oncol. 2018 Apr;13(4):533-542
pubmed: 29246833
Ann Thorac Surg. 2017 Jul;104(1):313-320
pubmed: 28433219
Ann Thorac Surg. 2019 Jul;108(1):249-255
pubmed: 30876742
Anticancer Res. 2019 May;39(5):2665-2670
pubmed: 31092466

Auteurs

Kenichi Suda (K)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. katsu-sato@med.kindai.ac.jp.

Masaki Shimoji (M)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. mshimoji@med.kindai.ac.jp.
Department of Thoracic Surgery, Izumi City General Hospital, Izumi 594-1101, Japan. mshimoji@med.kindai.ac.jp.

Shigeki Shimizu (S)

Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama 594-0073, Japan. shimizush@med.kindai.ac.jp.

Katsuaki Sato (K)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan.
Department of Thoracic Surgery, Izumi City General Hospital, Izumi 594-1101, Japan.

Masato Chiba (M)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. m-chiba@med.kindai.ac.jp.

Kenji Tomizawa (K)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. ktomizawa@med.kindai.ac.jp.
Department of Thoracic Surgery, Izumi City General Hospital, Izumi 594-1101, Japan. ktomizawa@med.kindai.ac.jp.

Toshiki Takemoto (T)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. takemoto@med.kindai.ac.jp.

Junichi Soh (J)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. soh.j@med.kindai.ac.jp.

Tetsuya Mitsudomi (T)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. mitsudom@med.kindai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH